FRT [OUTPERFORM +12.7%] - Pharmacy to contribute major earnings over next five years - Update
  • 2023-06-30T00:00:00
  • Company Research

- We increase our target price (TP) for FRT by 19% but downgrade our rating from BUY to OUTPERFORM as the company’s share price has rallied ~29% over the last month. 

- Our higher TP is because we increase our valuation for the Long Chau (LC) pharmacy chain by 23% due to (1) increasing our aggregate 2025F-29F sales by 18% as we raise our assumption for LC’s 2029F store count to 3,000 from 2,600 as a result of our more optimistic view about LC’s store expansion capability from now to 2029, and (2) extending our explicit forecast horizon to 2033 from 2032 as previously.

Powered by Froala Editor